A patient-reported worst joint pain score of 4 or greater on the BPI is a significant predictor of premature discontinuation of aromatase inhibitors (hazard ratio 2.09, P = 0.016)37, leading to increased cancer recurrence and higher mortality rates12,38. Here, CYP19A1 is linked to cancer.